Reagents and instruments for immunology, cell biology and molecular biology.
 
> Gefitinib [184475-35-2]

Gefitinib [184475-35-2]

Print Print
Please log in

Cat# 10-1148-250mg

Size : 250mg

Brand : Focus Biomolecules

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Gefitinib | EGFR kinase inhibitor

CAS:
184475-35-2
Catalog Number:
10-1148
Activity:
EGFR-Kinase inhibitor
Alternate Names:
ZD1839, Iressa
Chemical Name:
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Molecular Weight:
446.91
Molecular Formula:
C22H24ClFN4O3
Solubility:
Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).
Physical Properties:
Tan solid
Purity:
98% by TLC
NMR (Conforms)
Storage Temperature:
RT
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
Shipping Code:
RT

Available Options

size :Quantity 
50 mg$30.00
250 mg$66.00
Request Quote / Bulk / Custom Size
Product Inquiry

Gefitinib (184475-35-2) is a potent and selective EGFR kinase inhibitor (IC50 = 23-79 nM).1 Inhibits EGFR autophosphorylation and inhibits tumor growth in vivo.2 Enhances efficacy of cytotoxic agents.3 Inhibits growth factor production and angiogenesis.4 Clinically useful anticancer agent.

References/Citations:

1) Baselga et al. (2000), ZD1839 (‘Iressa’) as an anticancer agent; Drugs, 60 33
2) McKillop et al. (2005), Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; Mol. Cancer Ther., 4 641
3) Sirotnak et al. (2000), Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase; Clin. Cancer Res., 6 4885
4) Ciaradiello et al. (2001), Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor; Clin. Cancer Res., 7 1459

184475-35-2, EGFR Kinase Inhibitor, Gefitinib supplier
CAS:
184475-35-2
Catalog Number:
10-1148
Activity:
EGFR-Kinase inhibitor
Alternate Names:
ZD1839, Iressa
Chemical Name:
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
Molecular Weight:
446.91
Molecular Formula:
C22H24ClFN4O3
Solubility:
Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).
Physical Properties:
Tan solid
Purity:
98% by TLC
NMR (Conforms)
Storage Temperature:
RT
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee

Gefitinib (184475-35-2) is a potent and selective EGFR kinase inhibitor (IC50 = 23-79 nM).1 Inhibits EGFR autophosphorylation and inhibits tumor growth in vivo.2 Enhances efficacy of cytotoxic agents.3 Inhibits growth factor production and angiogenesis.4 Clinically useful anticancer agent.

References/Citations:

1) Baselga et al. (2000), ZD1839 (‘Iressa’) as an anticancer agent; Drugs, 60 33
2) McKillop et al. (2005), Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; Mol. Cancer Ther., 4 641
3) Sirotnak et al. (2000), Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase; Clin. Cancer Res., 6 4885
4) Ciaradiello et al. (2001), Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor; Clin. Cancer Res., 7 1459